EGFR and head and neck squamous cell carcinoma: Further, EGFR inhibitors or blockade of the EGFR protein with selective monoclonal antibodies sensitized cancer cells to radiation therapy by blocking the repair of damaged DNA (39) and improved clinical outcomes in a subset of patients with head and neck squamous cell carcinoma (131).